© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Chlorpromazine hydrochloride changed the landscape of psychiatric care when it entered the market back in the early 1950s. French scientists synthesized it at a time when mental health wards looked grim, with people locked away for years without much hope. Once doctors started using it for psychosis, especially schizophrenia, everything shifted for institutional care. Before this, beds filled up with patients who rarely left. Afterward, more people returned to their families and communities. This wasn’t some accidental discovery; researchers were chasing safer antihistamines and ended up finding something far greater. Its effect on dopamine introduced a new line of antipsychotic drugs and set a benchmark for future chemical interventions in psychiatry. Many psychiatrists from earlier generations remember the before-and-after difference, not just in clinical charts but in the sheer sound level of psychiatric wards: less screaming, fewer restraints, more conversations. Stories from that time sound almost mythical, but medical journals and decades of case studies confirm chlorpromazine’s pivotal role.
In pharmacy storerooms and hospital cabinets, chlorpromazine hydrochloride typically appears as a white or slightly off-white, crystalline powder. Companies produce tablets, syrups, and injectable forms, each with a slightly different set of excipients, but all delivering that signature calming effect on agitated minds. On packaging, the drug usually carries dosage strengths ranging from 10 mg to 100 mg. Pharmaceutical wholesalers recognize it under brand names such as Thorazine and Largactil. Regulatory agencies require clear labeling with strict dosages because the difference between helpful and harmful isn’t just theoretical; a simple decimal misplacement can seriously risk patient safety. Patients prescribed chlorpromazine tend to remember its strong sedative effect, some describing a kind of “mental quietness” they hadn’t felt in years.
Chlorpromazine hydrochloride comes as a stable, odorless powder, soluble in water and slightly bitter to the taste. Chemical formulas don’t usually make for compelling stories, but C17H19ClN2S·HCl translates to a structure that binds selectively to dopamine D2 receptors. Its melting point hovers around 193-198°C; this stability allows long shelf lives for hospital stocks. Light can degrade it though, so amber vials and tight packaging matter more than many might guess. Keeping the compound away from air and bright environments preserves its efficacy, proven both by chemical tests and pharmacists’ anecdotes about expired batches losing their punch. One key detail: chlorpromazine’s hydrochloride salt increases its water-solubility, making it possible to inject or mix into liquid suspensions, options that prove invaluable for patients unable to swallow tablets.
Strong regulatory standards surround chlorpromazine. Labels detail the active pharmaceutical ingredient percentage, commonly requiring a content of 98-102% relative to the labeled claim following pharmacopeia standards (USP, EP, JP). Impurity limits stay tight—often less than 0.5% for functionally related impurities. Moisture content and residual solvents face scrutiny during manufacturing, since small variations in purity can lead to inconsistent dosing. Authorized manufacturers print storage conditions directly on the box, reminding anyone handling it to keep the medicine below 30°C and out of direct light. Each unit comes with clear warnings about sedation, driving, and the risk of extrapyramidal symptoms. Pharmacies can face fines or even closures if inspectors catch substandard labeling or outdated quality control certificates, echoing the importance of maintaining high operational standards.
Pharmaceutical-grade chlorpromazine hydrochloride comes from a well-established synthesis path. Manufacturers usually begin with phenothiazine as the starting structure, modifying it through alkylation and introducing a propyl chain. The hydrochloride salt forms through reaction with hydrochloric acid, with purification involving crystallization and multiple filtrations. Running these reactions demands precision in pH and temperature—close enough to medical research labs rather than basic chemical plants. Over the years, green chemistry trends have nudged manufacturers toward less polluting reagents and solvents, driven by both regulatory pressure and cost savings. These tweaks lower the environmental impact for bulk suppliers while ensuring that the final product meets strict pharmaceutical regulations on purity and safety.
Chemists find phenothiazine derivatives endlessly fascinating. Chlorpromazine’s core structure accepts modifications on its side chains and ring locations, changing its potency, sedative properties, and even its potential side effects. Medicinal chemists experimented by adding different groups—ethyl, methyl, halogens—to various positions, hoping to amplify antipsychotic effects or reduce adverse reactions like weight gain or muscle stiffness. These variants have laid the groundwork for new antipsychotics and some antiemetic drugs currently on formulary lists. Studies in structure-activity relationships show even slight tweaks in the molecule can have broad consequences, turning a mild tranquilizer into something with potent activity. Newer research also explores prodrugs and depot injections, aiming for longer release profiles and improved patient compliance, as nobody loves daily pills or constant injections.
In the medical world, one chemical often carries many names. Chlorpromazine hydrochloride is no different. Pharmacists and physicians might list it as Thorazine, Largactil, or simply “CPZ.” Other synonyms pop up in literature: 2-chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride, or even its catalog number for scientific reference (CAS: 69-09-0). Even after decades, these names retain weight in psychiatric circles, echoing across patient charts, pharmacology textbooks, and regulatory filings. This multiplicity of names can trip up new staff or those scanning drug interaction checklists, emphasizing the always-present risk of name-based medication errors.
Handling chlorpromazine requires more than just standard gloves—it takes experience. Direct skin contact brings risk of irritation, and dust inhalation can hit staff with unintended effects ranging from mild dizziness to severe drowsiness. Pharmaceutical plants enforce fume hoods, protective goggles, and frequent air monitoring. Hospitals keep antidotes and detailed protocols on hand for overdoses, which can lead to severe hypotension, cardiac arrhythmias, or even life-threatening neuroleptic malignant syndrome. Regular staff training updates play a critical part in keeping use safe, especially across psychiatric and emergency medicine units. Each new nurse or pharmacist learns chlorpromazine’s interaction risk, especially with anticoagulants, CNS depressants, and medications affecting the QT interval. Regulatory bodies expect strict logs for every batch’s journey from synthesis to patient, and violations often attract steep penalties.
Uses for chlorpromazine stretch further than most people realize. In psychiatry, it stands as a reliable antipsychotic for schizophrenia and severe behavioral disturbances. Emergency rooms count on it as a chemical restraint for acute agitation. Some oncologists prescribe it off-label to reduce intractable nausea for chemotherapy patients, especially those who can’t tolerate newer drugs. It also remains one of the few lines of defense against severe hiccups, a medical oddity that reappears periodically in case reports. Low-income countries use chlorpromazine more often than expensive atypical antipsychotics due to cost and proven track records. Countless clinical guidelines mention its role not just for symptoms control, but as a fallback when other agents don't fit the bill, reflecting decades of cross-specialty experience.
Chlorpromazine keeps attracting researchers’ interest even after more than half a century. Studies often compare it to new antipsychotic agents in head-to-head trials, trying to see who fares better in real-world settings. University teams test subtle chemical modifications, searching for better safety or tailored effects for subgroups like elderly patients. Public health offices sponsor projects tracking its effect on population-level outcomes, especially in areas without access to expensive alternatives. Preclinical research also explores its surprising antiviral and antiparasitic properties, hinting at new uses outside psychiatry. Ongoing work follows patients who switched from chlorpromazine to newer agents and revisits old data sets, picking over long-term outcomes with modern analytics.
Toxicologists and clinicians keep close tabs on chlorpromazine’s side effects. High doses often lead to anticholinergic symptoms—dry mouth, blurred vision, constipation—and carry real danger of cardiovascular collapse. Liver metabolism adds complexity, as impaired hepatic function can quickly turn a therapeutic dose toxic. Rare but devastating risks include neuroleptic malignant syndrome, a medical emergency that every psychiatric ward prepares to handle. Decades of case reports and animal studies map out its cardiac, renal, and CNS toxicity profiles, giving doctors clear parameters for safe use. Dose adjustments for children, elderly patients, and those with organ impairment reflect this hard-won experience. Poison control centers continue reporting on accidental overdoses, driving further research into safer analogs and more user-friendly formulations.
Chlorpromazine’s future looks far from over, though its star has dimmed since the introduction of second-generation antipsychotics. As treatment-resistant psychosis remains a major problem worldwide, many psychiatrists revisit its broad dopamine-blocking effect for tough cases that don’t respond to newer drugs. Generic status and low cost guarantee its place in public health formularies, especially in developing regions. Ongoing research into drug delivery systems, such as long-acting injectables or subcutaneous depots, might breathe new life into its use. Environmental and production safety improvements continue to advance, making chlorpromazine more sustainable and less polluting for mass production. Perhaps most importantly, the drug’s long-term safety record, often viewed with scrutiny, also serves as a valuable baseline for future neuropsychiatric research, giving new medicines a benchmark to meet or surpass.
Chlorpromazine Hydrochloride, mostly known as Thorazine, made a huge impact in psychiatry back in the 1950s. Before it showed up, people living with conditions like schizophrenia often faced long-term stays in state hospitals, sometimes with little hope for relief. The arrival of chlorpromazine changed that story. Some even say it opened the door to modern psychiatric treatment. I remember a professor in med school telling us stories about families who noticed their loved ones becoming calmer and more aware, just days after starting this medication. The difference for many was nothing short of remarkable.
This medicine works mostly for people struggling with psychotic disorders. Hallucinations, paranoia, and delusions can make life confusing or even scary. Chlorpromazine blocks certain chemicals in the brain, called dopamine receptors, that are involved in these symptoms. By quieting that chemical storm, it can bring reality back into focus. That’s why psychiatrists reach for it during severe episodes of schizophrenia, acute manic episodes in bipolar disorder, and sometimes for major agitation in dementia.
I’ve seen cases where someone arrives at the emergency room upset and scared, convinced that everyone is out to get them. After a dose or two, they begin to settle, sometimes even able to talk about their fears without panic. For families and care teams, that’s a big deal. It means people can return to their homes sooner, take part in their lives, and have some hope of stability.
Doctors don’t only use chlorpromazine for psychiatric problems. It can also calm severe nausea and vomiting, including nausea from chemotherapy that won’t respond to regular treatments. In rare situations, severe hiccups that last for days—yes, that’s a real thing—respond to chlorpromazine when little else works. Some people with tetanus experience muscle spasms and agitation, so doctors give chlorpromazine as part of their strategy to help control those symptoms.
Chlorpromazine changed mental health, but it came with baggage. The side effects can be tough, especially for older adults or those on higher doses. Shuffling walk, rigid muscles, and tremors can look a lot like Parkinson’s disease. I’ve known folks who felt trapped in their own bodies because of a problem called tardive dyskinesia—uncontrollable movements, often in the face and tongue, that don’t always go away. Weight gain, dry mouth, blurry vision, and a strong sedative effect can make everyday activities harder. For some, these side effects are just as challenging as the symptoms the medicine is supposed to treat.
Because of its side effect profile, newer antipsychotic drugs often get picked first. Chlorpromazine remains on the list, though, especially in places where the newer medicines cost too much or aren’t available. Sometimes a patient just responds better to it. That’s an important reminder: mental health treatment isn’t one-size-fits-all. It takes trial, error, and listening to people about how they feel on their medicine.
Better monitoring reduces the risks linked with chlorpromazine. Regular doctor visits matter. Blood work, movement checks, and honest conversations about side effects help keep people safe. In an ideal world, every community would offer a full menu of medication options plus counseling, job support, and safe housing. The reality looks different in many places. So for some, having access to chlorpromazine still means a chance at a better life, even with its challenges. And that’s not a story from the textbooks—it’s one that continues to unfold for families everywhere.
Chlorpromazine Hydrochloride has a long history in mental health treatment, especially for psychosis and severe agitation. Doctors often reach for it to calm patients who feel overwhelmed by their symptoms. Once a person takes chlorpromazine, it's clear pretty quickly if the body agrees with it or not.
Some folks feel groggy or sedated. This tiredness can hit hard, almost wiping out the rest of the day. Energy drops, making regular tasks feel more demanding than usual. Dry mouth shows up often, even with just a few doses. A glass of water helps, but some people end up carrying gum or mints just to deal with feeling parched.
Weight usually creeps up after a few weeks. People may not expect this surprise, yet appetite often surges with steady use. Clothes get tight, belts move out a notch or two. Fluid retention adds to the number on the scale, sometimes causing swelling around the ankles.
Stiffness is a big complaint. Simple moves like stretching an arm or bending a knee start to feel unnatural for some. Legs feel restless at night or during quiet times, a sensation far more than just being fidgety. Muscle spasms and unusual face movements come into play with regular or long-term use. For many, this side of things leads to long talks about trying something new or adjusting the dose.
People sometimes feel shaky, almost like after too much coffee. Tremors set in, and for those whose livelihoods involve steadiness—say, using tools or writing—this takes a toll. Walking can become awkward, showing up as a slow shuffle.
Stomach troubles are routine. Nausea might start on day one for new users. Constipation hits many, making bathroom runs frustratingly rare. Some find themselves reaching for fiber supplements or talking to their doctors about safe laxatives.
Low blood pressure stands out as a risk, causing sudden dizziness. Standing up too fast in the morning can bring on head rushes or blurry vision. Older patients, in particular, talk about falls due to these spells, so many start rising out of bed slower, holding onto something solid for a moment.
Nobody wants to trade one set of problems for another. Honest, ongoing conversations with healthcare providers matter. It helps to keep track of changes, whether that's more naps needed or struggles with nausea. Blood tests happen from time to time to check in on liver health and white blood cell counts, since problems can lurk quietly.
Regular exercise and mindful eating hold some weight in controlling side effects. Hydration and simple routines make the new normal more bearable. Family, friends, and support groups often step into the picture, offering practical help—driving to appointments, cooking when energy tanks, and keeping moods steady.
Chlorpromazine doesn’t suit everyone. Doctors sometimes adjust the dose or consider different medications if the trade-offs get too harsh. Looking at side effects head-on, searching for practical ways to cope, and looping in trusted health professionals always makes a difference.
Chlorpromazine Hydrochloride changed the way doctors manage symptoms of mental health struggles such as schizophrenia, severe agitation, and some nausea disorders. Known by many as Thorazine, this medicine came on the scene in the early 1950s. It worked so well that it set the tone for a new class of psychiatric medications. Today, people still rely on it—but only with clear, careful use.
Chlorpromazine comes as a tablet, syrup, and as an injection. In most cases, doctors work with you to pick a form that fits your life and medical needs. Tablets and syrup get taken by mouth. Some hospital patients use injections during emergencies, especially for quick calming in serious agitation. Home doses start low; nobody jumps straight to a high dose. The idea’s simple: find the lowest amount to get symptoms under control while keeping side effects away.
Ignoring the package or doctor’s instructions can sour the whole treatment. Some think doubling up after a missed dose helps, but that’s a fast way to trouble—side effects like dizziness, low blood pressure, or even involuntary movements can sneak up. Long-term use calls for regular check-ins to spot and manage any new problems, like muscle stiffness or jaundice. Blood tests, eye exams, and heart checks often stay part of the routine.
Some folks like to take their pills with food if stomach upset knocks. It’s not a deal breaker, but the main thing’s staying on schedule, every day, and letting the doctor know about other medicines or supplements. Lots of over-the-counter products mess with the way chlorpromazine works—cough syrup, allergy meds, alcohol, and stuff for sleep can really turn up the risk of drowsiness or heart trouble.
Chlorpromazine does more than just treat symptoms. Mouth dryness, weight gain, or blurry vision often show up in daily life. I’ve watched relatives work with their pharmacist to manage dry mouth—sucking on sugar-free candy or staying hydrated can help. Sunburn comes easier while using this medicine, so sunscreen and hats keep skin safer on sunny days. Tardive dyskinesia—jerky face or limb movements—can hit if the medicine stays in play too long without proper review. That’s why honest talks at each visit make a huge difference.
I helped care for a family member who needed chlorpromazine for years. Setting alarms, using pill organizers, and writing down questions for our doctor helped lower stress and avoid mix-ups. Keeping information simple made them feel more confident. They knew what each pill was for, and that trust helped everything feel a little more manageable.
Not every pharmacy keeps every dose in stock, and insurance can get tricky. Talking to your pharmacist pays off—they can talk about generics or set up reminders. Support groups for mental health also share tips on managing medication routines and speaking up at doctor’s visits. Real experience, not just pamphlets, helps people feel less alone.
Chlorpromazine hydrochloride has a reputation for changing lives in psychiatry. Its story goes back decades, bringing relief to people facing schizophrenia and other tough mental health challenges. At the same time, the risks attached to this drug demand serious attention. No medication with real power comes without real consequences.
Many doctors, including those I’ve talked with over the years, rely on chlorpromazine for emergencies when symptoms run high. It can quiet a storm of agitation or hallucinations that nothing else seems to touch. But stories from hospital wards are filled with patients who’ve experienced more than just relief. Sedation often shows up quickly, and with it, a heavy fog sets in—a kind of tiredness most folks don’t expect. Friends in nursing and pharmacy have seen patients unable to get out of bed, missing meals, their muscles stiff, drooling or slurring their words. This drug can pull the brakes far too hard on the nervous system.
Tardive dyskinesia emerges in some who use chlorpromazine for a long time. This shows up as twitching of the face or body movements you can’t hide or control. One doctor told me these effects haunt patients long after they stop the drug, stealing confidence and dignity. These movement problems don’t have an easy fix, often hanging around for life.
Doctors get worried about a risky drop in blood pressure known as orthostatic hypotension. Patients trying to stand up after a dose can get dizzy, fall, or black out. Those not used to this risk discover it in bruises or worse injuries. People sometimes arrive in the ER confused, clutching the arm of a nurse, with little memory of what just happened.
Neuroleptic malignant syndrome stands out as the nightmare scenario. This rare reaction hits like a freight train—high fever, rigid muscles, and racing heart. It can land a patient in the intensive care unit. The risk rises if a hospital doesn’t spot it fast enough. No one forgets a case like that, least of all the people who survive it.
Chlorpromazine triggers other warning signs: jaundice from liver damage, risk of seizures, and changes in heart rhythm that can turn deadly, especially in those with other health problems. Prolonged QT interval sounds technical, but it means the heart is struggling with its beat, and that can spell sudden death. Older adults face a sharper threat of pneumonia or stroke.
Overdoses bring their own dangers, mostly seen in psychiatric units, but sometimes involving children who come across old prescriptions. Respiratory problems, heart issues, and deep coma set the stage for real tragedy.
Clear discussion wins out over blind trust. Doctors who know this drug well lay out every risk and check heart and liver health before starting it. Regular monitoring—EKGs and blood tests—catch early signs of trouble. Families should keep old medicines locked up or gone for good.
Newer antipsychotics often offer similar benefits with fewer long-term risks, and many mental health teams now reach for those as first-line therapies. Chlorpromazine still has a place but it shouldn’t be handed out without weighing each risk, listening to patient families, and watching for problems—every single day.
Chlorpromazine Hydrochloride has decades of history as an antipsychotic. Doctors prescribe it for schizophrenia, bipolar disorder, and even nausea—not much has changed in that respect. Over time, pharmacists started noticing that chlorpromazine often gets paired with other drugs because people rarely deal with just one condition at a time. This sets the stage for possible drug interactions that affect real lives every week.
I remember standing at the pharmacy counter as a young intern, watching a patient drop off prescriptions for high blood pressure, diabetes, and new antipsychotics. That’s typical. Chlorpromazine has a clever way of making trouble by playing around with how other drugs work. It can make antihypertensives push blood pressure too low, turning a safe dose risky. Combination with antidepressants or other antipsychotics can lead to drowsiness, dizziness, or even more dangerous conditions like neuroleptic malignant syndrome, which can be fatal.
According to the Food and Drug Administration (FDA), chlorpromazine affects how the liver processes enzymes (CYP450 enzymes in particular). These enzymes handle many different drugs, so medications that alter enzyme activity can change how much chlorpromazine stays active in the body. Take fluoxetine (Prozac). This common antidepressant slows down enzyme activity, meaning chlorpromazine hangs around longer, increasing its side effects. People start feeling groggy, movement slows, tremors creep in, and confusion isn’t just a nuisance—it can lead to hospitalization.
One overlooked danger is the risk of heart rhythm problems. Chlorpromazine, on its own, can cause long QT syndrome. Add certain antibiotics or antiarrhythmics, and the risk of a deadly arrhythmia jumps. According to Mayo Clinic and peer-reviewed studies, mixing this antipsychotic with medications that prolong the QT interval is a recipe for ER visits. Seniors and people with heart conditions deserve extra attention—for them, a minor interaction can be life-threatening.
Doctors, pharmacists, and patients need stronger awareness of these risks. Stories of adverse events keep surfacing, from mild confusion to sudden collapses. One of my old mentors hammered home the habit of double-checking for drug interactions with every refill or new prescription. That focus can stop problems before they start.
Patients often have a long list of meds. Different doctors may not always exchange notes or updates. Simple fixes exist, like carrying a complete medication list in your wallet or keeping a digital record updated on your phone. Pharmacists serve as the last defense line. They catch dozens of potential disasters—provided people tell them about all the meds they take, including over-the-counter options or supplements.
A recent survey in JAMA revealed almost half of adults take at least one prescription medication, and about 20% use five or more. With those numbers, serious drug interactions such as those with chlorpromazine are more likely than ever. People can protect themselves by asking direct questions at every medical visit: Is it safe to take these together? What side effects mean it’s time to call the doctor?
Drug interactions with chlorpromazine are not just a few lines in the fine print—they matter to people managing tough illnesses. With clear conversations and solid information, most of these hazards stay manageable. Doctors and patients, by staying alert, can keep old remedies like chlorpromazine from causing new problems.
| Names | |
| Preferred IUPAC name | 2-chloro-N,N-dimethyl-10H-phenothiazine-10-ethanamine hydrochloride |
| Other names |
Thorazine Largactil CPZ Chlorpromazin Chlorpromazine HCl |
| Pronunciation | /klɔːrˈprəʊməziːn haɪˌdrɒklaɪˈraɪd/ |
| Identifiers | |
| CAS Number | 69-09-0 |
| Beilstein Reference | 1364701 |
| ChEBI | CHEBI:3643 |
| ChEMBL | CHEMBL941 |
| ChemSpider | 14033 |
| DrugBank | DB00477 |
| ECHA InfoCard | 100.029.341 |
| EC Number | 1.7.99.1 |
| Gmelin Reference | 14649 |
| KEGG | D07830 |
| MeSH | D002706 |
| PubChem CID | 6603700 |
| RTECS number | BP4550000 |
| UNII | 1313VP549D |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C17H19ClN2S·HCl |
| Molar mass | 355.33 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.1 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 5.3 |
| Acidity (pKa) | 9.3 |
| Basicity (pKb) | 9.3 |
| Magnetic susceptibility (χ) | -25.6×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.668 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.16 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 324 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -306.8 kJ/mol |
| Pharmacology | |
| ATC code | N05AA01 |
| Hazards | |
| Main hazards | Toxic if swallowed, causes serious eye irritation, may cause drowsiness or dizziness, suspected of causing genetic defects. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Harmful if swallowed. Causes serious eye irritation. May cause drowsiness or dizziness. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Autoignition temperature | > 510°C (950°F; 783 K) |
| Lethal dose or concentration | LD50 Rat oral 750 mg/kg |
| LD50 (median dose) | LD50 (median dose): 360 mg/kg (rat, oral) |
| PEL (Permissible) | PEL: 2 mg/m³ |
| REL (Recommended) | 50-300 mg/day |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Promazine Trifluoperazine Perphenazine Fluphenazine Thioridazine Mesoridazine Prochlorperazine Levomepromazine |
